Intellia Therapeutics' stock surged 5.77% in pre-market trading on Wednesday, showing strong upward momentum ahead of the regular session.
The sharp rise follows an analyst upgrade from Jonestrading, which raised its rating on Intellia Therapeutics from Hold to Buy, signaling increased confidence in the company's prospects.